Sign In
Buy JNJ
$231.29
+2.90 (+1.27%)
At Close: Jun 22, 2026
Bank of America Tumbles 7% While Verizon, J&J, and Chevron Rally on Dividend Hikes
08:10am, Tuesday, 17'th Feb 2026
Blue-chip dividend stocks delivered mixed returns last week as investors weighed earnings reports, dividend announcements, and shifting interest rate expectations.
Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2 Builds on RYBREVANT FASPRO™ FDA approval to deliver the simplest and fastest combination regimen for EGFR
Dividend Income: Lanny's December 2025 Summary
06:23am, Tuesday, 17'th Feb 2026
In December, we received a dividend income total of $8,010.54. The retirement accounts are composed of HSA investments, ROTH and traditional IRAs, as well as our work 401(k) accounts. In total, divide
Beirne Wealth Consulting Services LLC Acquires New Position in Johnson & Johnson $JNJ
05:05am, Tuesday, 17'th Feb 2026
Beirne Wealth Consulting Services LLC bought a new position in shares of Johnson and Johnson (NYSE: JNJ) during the undefined quarter, according to the company in its most recent filing with the SEC.
J&J's MedTech Shows Strong Growth in 2025: Will 2026 be Better?
10:55am, Monday, 16'th Feb 2026
Johnson & Johnson's JNJ medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J's
Johnson & Johnson $JNJ Shares Purchased by Fifth Third Bancorp
04:28am, Monday, 16'th Feb 2026
Fifth Third Bancorp boosted its position in shares of Johnson and Johnson (NYSE: JNJ) by 7.0% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 1,13
Jury: Johnson & Johnson Liabile in Case Linking Baby Powder to Cancer
03:41pm, Saturday, 14'th Feb 2026
On Friday, a Pennsylvania state-court jury in Philadelphia ordered Johnson and Johnson (NYSE: JNJ) to pay $250,000 to the family of Gayle Emerson, finding the company liable in a case blaming its talc
Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K
04:19pm, Friday, 13'th Feb 2026
The plaintiff used J&J's baby powder from 1969 until 2017. She sued in 2019 and died six months later at the age of 68.
Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial
04:18pm, Friday, 13'th Feb 2026
PHILADELPHIA--(BUSINESS WIRE)--A jury in the Philadelphia Court of Common Pleas has found Johnson & Johnson (NYSE:JNJ) responsible for the company's baby powder products contributing to the death of a
Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial
02:43pm, Friday, 13'th Feb 2026
A jury in Pennsylvania state court on Friday awarded $250,000 to the family of a woman who sued Johnson & Johnson alleging its talc-based baby powder was to blame for her ovarian cancer, according to
After A 55% Surge, Is JNJ Stock Still A Buy?
07:00am, Friday, 13'th Feb 2026
Johnson & Johnson (JNJ) stock is currently at a notable juncture. It exhibits strong momentum, up 55% in the last twelve months, and investing in it entails support for a company characterized by robu
Drake & Associates LLC Sells 7,105 Shares of Johnson & Johnson $JNJ
05:17am, Thursday, 12'th Feb 2026
Drake and Associates LLC decreased its stake in shares of Johnson and Johnson (NYSE: JNJ) by 32.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange C
NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review
02:23pm, Wednesday, 11'th Feb 2026
The National Institutes of Health (NIH) on Tuesday discontinued the low-dose rivaroxaban arm of its ongoing Phase 3 CAPTIVA stroke prevention trial.
Is Johnson & Johnson a Buy, Sell, or Hold in 2026?
09:45pm, Tuesday, 10'th Feb 2026
Johnson & Johnson has crushed the market over the past year. The healthcare giant faces some challenges that could harm its results.
SVB Wealth LLC Trims Stake in Johnson & Johnson $JNJ
05:14am, Tuesday, 10'th Feb 2026
SVB Wealth LLC cut its stake in Johnson and Johnson (NYSE: JNJ) by 8.3% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm ow
